Development of a Battery of Audiological Tests for the Precision Diagnosis of Age-related Hearing Loss

Overview

Age-related hearing loss, or presbycusis, is caused by many genetic and environmental factors. Its prevalence poses a public health challenge of early identification and effective hearing aid treatment. However, the lack of screening and of a validated audiological test battery to diagnose an individual's needs and to guide hearing aid adjustments is a major obstacle. Furthermore, monogenic forms of hearing loss affect only one functional module of hearing. The audiological test(s) dependent on the function of this module are affected, in a progressive manner, but not the others. A previous study showed that in early onset presbycusis patients, a quarter of the subjects tested were affected by monogenic presbycusis. The collection of audiological and vestibular tests, carried out on proven monogenic presbycusis patients and compared to that of normal hearing patients, would constitute a battery of tests allowing a precision diagnosis, then developed to all forms of presbycusis in order to study if the identification of abnormal functional modules can usefully guide the diagnosis and the early fitting.

Detailed description

The AUDIOGENAGE project is a multi-center, non-invasive case-control study conducted by CERIAH (CEntre de Recherche et d'Innovation en Human Audiology) and LCA (Laboratory de correction auditive) in 700 volunteer participants identified in two groups:

* 500 Patients with age-related hearing loss of anticipated onset, * 200 Control subjects, considered as normal hearing for their age at inclusion.

All participants will undergo 6h audiological and vestibular tests, and also neurocognitive test (self-questionnaire). These tests will be conducted over 2 to 4 visits. A 10 mL-blood sample will be collected for a genetic analysis.

Interventions

• Other Audiological and vestibular tests
  6h of audiological and vestibular tests divide in 3 sessions : * Session A : objective audiological tests * Session B ; subjective audiological tests * Session C : balance tests.
• Other Blood sampling
  A 10 mL blood sample will be collected during the study.
• Other neurocognitive self-questionnaire
  Four self-questionnaires to fill out to measure sleep quality, memory and emotional state

Primary outcome measures

• Measurement of specificity and sensitivity of the audiological test battery in participants with early-onset presbycusis after identification of pathogenic variants by sequencing and division into subgroups. [Time frame: 2 years]

Secondary outcome measures (2)

• Normative values for audiological and vestibular tests will be determined [Time frame: 4 years and 6 months]
• Whole-exome sequencing of samples from participants with non-monogenic presbycusis [Time frame: 4 years and 6 months]

Eligibility criteria

Inclusion criteria

For all participants:

• Be over the age of 18,
• Be affiliated to a social security system,
• Have a good command of the French language (oral and written).

For the group of participants with anticipated presbycusis:

• Over the age of 40, having a hearing aid recipient or coming for a first hearing aid recipient
• Between 18 and 40, having a hearing aid recipient, coming for a first hearing aid recipient or declare a progressive genetic birth defect

For healthy volunteers:

\- Have no known hearing loss.

Exclusion criteria

• Report having been chronically exposed to loud sounds.
• Have a history of ototoxic substances,
• To have sequelae of ear infections and/or a history of ENT disease that permanently affects hearing or balance,
• Have an ethnic origin for which the Pasteur Institute does not have information on the frequency of variants of the genes studied.
• Have type II diabetes,
• Have a neurological or psychiatric condition that interferes with comprehension or ability to move,
• Be under guardianship,
• Be deprived of liberty by judicial or administrative decision, or be subject to legal protection,
• Not being subject to a social security system,
• Taking narcotic substances, alcohol or medication that diminishes cognitive abilities.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Diagnostic

Study locations

France · 2 centers

• Laboratoire de correction auditive — Paris
• CEntre de Recherche et d'Innovation en Audiologie Humaine — Paris

Identifiers

NCT: NCT05312983 · 2021-062 · 2021-A02543-38

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗